Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report released on Tuesday morning,Benzinga reports. They currently have a $38.00 price objective on the stock.

PVLA has been the subject of a number of other research reports. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price for the company. Stifel Nicolaus assumed coverage on Palvella Therapeutics in a research report on Wednesday, March 26th. They set a “buy” rating and a $45.00 price objective for the company. Jones Trading began coverage on Palvella Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $45.00 target price on the stock. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $43.50.

Palvella Therapeutics Stock Down 9.4 %

Shares of Palvella Therapeutics stock opened at $24.43 on Tuesday. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $29.27. The stock has a market capitalization of $274.13 million, a P/E ratio of -2.02 and a beta of 0.54. The business has a 50 day moving average price of $21.25.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at about $125,000. Toronto Dominion Bank purchased a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $159,000. Geode Capital Management LLC acquired a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $171,000. Cresset Asset Management LLC purchased a new stake in Palvella Therapeutics in the 4th quarter valued at approximately $251,000. Finally, Renaissance Technologies LLC acquired a new stake in Palvella Therapeutics during the 4th quarter valued at $256,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.